Hosted on MSN

A day in Agios Andreas reveals hidden Greek charm

Agios Andreas in Kavala offers breathtaking views, traditional Greek architecture, authentic local culture, charming streets, and serene landscapes that make it a must-visit destination for travelers ...
The Hindu

Agios Pharma shares jump as U.S. FDA expands approval for blood disorder drug

Shares of Agios Pharmaceuticals (AGIO.O), jumped nearly 16% after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder. The drug, ...
Euronews

Can’t face battling the crowds at your favourite holiday spots next year? Choose these dupes instead

As overtourism and extreme heat take over several of Europe’s most popular southern destinations, more destination dupes are emerging for hotspots like Barcelona and Venice. This year has been a ...
Reuters

Agios Pharma shares jump as US FDA expands approval for blood disorder drug

Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO.O), opens new tab jumped nearly 16% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the ...
Investing

Agios Pharma stock price target raised to $62 from $48 at H.C. Wainwright

Agios expects Aqvesme to be available in late January 2026 following full REMS implementation. H.C. Wainwright updated its model to reflect a first-quarter 2026 commercial launch and increased the ...
Benzinga.com

FDA Approves Agios Drug For Thalassemia-Associated Anemia

The U.S. Food and Drug Administration (FDA) on Tuesday approved Agios Pharmaceuticals, Inc.’s (NASDAQ: AGIO) Aqvesme (mitapivat), an oral pyruvate kinase (PK) activator, for anemia in adults with ...
Yahoo Finance

Kosmos Energy (KOS) Price Targets Trimmed by Analysts

The share price of Kosmos Energy Ltd. (NYSE:KOS) fell by 10.68% between December 10 and December 17, 2025, putting it among the Energy Stocks that Lost the Most This Week. Kosmos Energy Ltd. (NYSE:KOS ...
Investing

FDA delays decision on Agios’ thalassemia drug application

CAMBRIDGE - The U.S. Food and Drug Administration (FDA) has not issued a decision on Agios Pharmaceuticals’ (NASDAQ:AGIO) supplemental New Drug Application (sNDA) for mitapivat by its expected ...
Nasdaq

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...
Yahoo Finance

Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market ...
Seeking Alpha

Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility

Agios Pharmaceuticals, Inc. stock plunged 49% after mixed Phase 3 results for mitapivat in Sickle Cell Disease, raising doubts about future approvals. Mitapivat met the primary hemoglobin endpoint but ...
The Motley Fool

Why Shares in Agios Pharmaceuticals Got Crushed Today

Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026. The trial was designed with two primary endpoints, and it hit ...